Axa
IOVA icon

Axa’s Iovance Biotherapeutics IOVA Stock Holding History

Axa’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,700
Closed -$775K – 1271
2020
Q4 		$775K Hold
16,700
– – ﹤0.01% 1013
2020
Q3 		$550K Hold
16,700
– – ﹤0.01% 1023
2020
Q2 		$458K Sell
16,700
-25,400
-60% -$835K ﹤0.01% 1075
2020
Q1 		$1.26M Buy
+42,100
New +$1.12M 0.01% 819
2019
Q1 		– Sell
-85,795
Closed -$759K – 1346
2018
Q4 		$759K Sell
85,795
-17,400
-17% -$168K ﹤0.01% 1014
2018
Q3 		$1.16M Hold
103,195
– – ﹤0.01% 1005
2018
Q2 		$1.32M Buy
103,195
+18,492
+22% +$270K 0.01% 943
2018
Q1 		$1.43M Sell
84,703
-584,272
-87% -$8.85M 0.01% 927
2017
Q4 		$5.35M Sell
668,975
-612
-0.1% -$4.91K 0.02% 630
2017
Q3 		$5.19M Sell
669,587
-9,180
-1% -$58.1K 0.02% 617
2017
Q2 		$4.99M Sell
678,767
-18,115
-3% -$115K 0.02% 607
2017
Q1 		$5.19M Buy
696,882
+364
+0.1% +$2.67K 0.02% 588
2016
Q4 		$4.84M Buy
696,518
+13,013
+2% +$89.5K 0.02% 591
2016
Q3 		$5.63M Sell
683,505
-84,256
-11% -$713K 0.02% 543
2016
Q2 		$6.22M Sell
767,761
-27,371
-3% -$172K 0.03% 519
2016
Q1 		$4.04M Buy
+795,132
New +$4.35M 0.02% 612

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Axa's IOVA Position: Q1 2021 in Review

Axa sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 16,700 shares — an estimated $775K sold.

Axa first reported a position in IOVA in Q1 2016 and held it in 16 quarters. The position peaked at $6.22M in Q2 2016. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Axa reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Axa sold 16,700 Iovance Biotherapeutics shares in Q1 2021, an estimated $775K.
  • Axa first reported a position in Iovance Biotherapeutics in Q1 2016 and held it in 16 quarters.
  • Axa's Iovance Biotherapeutics position peaked at $6.22M in Q2 2016.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.